Covid-19 Impact on Imatinib Drug Market, Global Research Reports 2020-2021

2 Global Imatinib Drug Quarterly Market Size Analysis

• 2.1 Imatinib Drug Business Impact Assessment - COVID-19
  • 2.1.1 Global Imatinib Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Imatinib Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Imatinib Drug Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Imatinib Drug Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Imatinib Drug Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Imatinib Drug Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Imatinib Drug Market
• 3.5 Key Manufacturers Imatinib Drug Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Imatinib Drug Segments, By Type

• 4.1 Introduction
  • 1.4.1 Tablets
  • 1.4.2 Capsules
• 4.2 By Type, Global Imatinib Drug Market Size, 2019-2021
  • 4.2.1 By Type, Global Imatinib Drug Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Imatinib Drug Price, 2020-2021

5 Impact of Covid-19 on Imatinib Drug Segments, By Application

• 5.1 Overview
  • 5.5.1 Chronic myelogenous leukemia
  • 5.5.2 Gastrointestinal stromal tumors
  • 5.5.3 Others
• 5.2 By Application, Global Imatinib Drug Market Size, 2019-2021
  • 5.2.1 By Application, Global Imatinib Drug Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Imatinib Drug Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Novartis
  • 7.1.1 Novartis Business Overview
  • 7.1.2 Novartis Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.1.3 Novartis Imatinib Drug Product Introduction
  • 7.1.4 Novartis Response to COVID-19 and Related Developments
• 7.2 Glenmark Pharmaceuticals Ltd.
  • 7.2.1 Glenmark Pharmaceuticals Ltd. Business Overview
  • 7.2.2 Glenmark Pharmaceuticals Ltd. Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.2.3 Glenmark Pharmaceuticals Ltd. Imatinib Drug Product Introduction
  • 7.2.4 Glenmark Pharmaceuticals Ltd. Response to COVID-19 and Related Developments
• 7.3 Sun Pharmaceuticals
  • 7.3.1 Sun Pharmaceuticals Business Overview
  • 7.3.2 Sun Pharmaceuticals Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.3.3 Sun Pharmaceuticals Imatinib Drug Product Introduction
  • 7.3.4 Sun Pharmaceuticals Response to COVID-19 and Related Developments
• 7.4 Actavis Generics
  • 7.4.1 Actavis Generics Business Overview
  • 7.4.2 Actavis Generics Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.4.3 Actavis Generics Imatinib Drug Product Introduction
  • 7.4.4 Actavis Generics Response to COVID-19 and Related Developments
• 7.5 Dr. Reddy's Laboratories
  • 7.5.1 Dr. Reddy's Laboratories Business Overview
  • 7.5.2 Dr. Reddy's Laboratories Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.5.3 Dr. Reddy's Laboratories Imatinib Drug Product Introduction
  • 7.5.4 Dr. Reddy's Laboratories Response to COVID-19 and Related Developments
• 7.6 Teva Pharmaceutical Industries Ltd.
  • 7.6.1 Teva Pharmaceutical Industries Ltd. Business Overview
  • 7.6.2 Teva Pharmaceutical Industries Ltd. Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.6.3 Teva Pharmaceutical Industries Ltd. Imatinib Drug Product Introduction
  • 7.6.4 Teva Pharmaceutical Industries Ltd. Response to COVID-19 and Related Developments
• 7.7 Sanofi S.A.
  • 7.7.1 Sanofi S.A. Business Overview
  • 7.7.2 Sanofi S.A. Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.7.3 Sanofi S.A. Imatinib Drug Product Introduction
  • 7.7.4 Sanofi S.A. Response to COVID-19 and Related Developments
• 7.8 Cipla Inc.
  • 7.8.1 Cipla Inc. Business Overview
  • 7.8.2 Cipla Inc. Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.8.3 Cipla Inc. Imatinib Drug Product Introduction
  • 7.8.4 Cipla Inc. Response to COVID-19 and Related Developments
• 7.9 Apotex Inc.
  • 7.9.1 Apotex Inc. Business Overview
  • 7.9.2 Apotex Inc. Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.9.3 Apotex Inc. Imatinib Drug Product Introduction
  • 7.9.4 Apotex Inc. Response to COVID-19 and Related Developments
• 7.10 Mylan Pharms Inc.
  • 7.10.1 Mylan Pharms Inc. Business Overview
  • 7.10.2 Mylan Pharms Inc. Imatinib Drug Quarterly Production and Revenue, 2020
  • 7.10.3 Mylan Pharms Inc. Imatinib Drug Product Introduction
  • 7.10.4 Mylan Pharms Inc. Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Imatinib Drug Supply Chain Analysis
  • 8.1.1 Imatinib Drug Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Imatinib Drug Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Imatinib Drug Distribution Channels
  • 8.2.2 Covid-19 Impact on Imatinib Drug Distribution Channels
  • 8.2.3 Imatinib Drug Distributors
• 8.3 Imatinib Drug Customers

9 Key Findings

10 Appendix

• 10.1 About Us